48,830
edits
Line 25: | Line 25: | ||
| Rads = | | Rads = | ||
| Endoscopy = | | Endoscopy = | ||
| Prognosis = | | Prognosis = moderate to good | ||
| Other = | | Other = | ||
| ClinDDx = other causes of lymphadenopathy - other [[lymphoma]]s, metastatic carcinoma | | ClinDDx = other causes of lymphadenopathy - other [[lymphoma]]s, metastatic carcinoma | ||
| Tx = | | Tx = | ||
}} | }} | ||
'''Follicular lymphoma''', abbreviated '''FL''', is a very common [[non-Hodgkin lymphoma]]. It is a [[small cell lymphoma]] | '''Follicular lymphoma''', abbreviated '''FL''', is a very common [[non-Hodgkin lymphoma]]. It is a [[small cell lymphoma]]. | ||
==General== | ==General== | ||
*A very common type of lymphoma. | *A very common type of lymphoma. | ||
* | *Moderate prognosis - overall five year survival ~ 66% in one cohort without transformation.<ref name=pmid23897955>{{Cite journal | last1 = Link | first1 = BK. | last2 = Maurer | first2 = MJ. | last3 = Nowakowski | first3 = GS. | last4 = Ansell | first4 = SM. | last5 = Macon | first5 = WR. | last6 = Syrbu | first6 = SI. | last7 = Slager | first7 = SL. | last8 = Thompson | first8 = CA. | last9 = Inwards | first9 = DJ. | title = Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. | journal = J Clin Oncol | volume = 31 | issue = 26 | pages = 3272-8 | month = Sep | year = 2013 | doi = 10.1200/JCO.2012.48.3990 | PMID = 23897955 }} | ||
*May transform to [[diffuse large B-cell lymphoma]]. | </ref> | ||
*May transform to a more aggressive lymphoma, e.g. [[diffuse large B-cell lymphoma]]. | |||
**Prognosis after transformation significantly worse - five year survival ~ 22%.<ref name=pmid23897955/> | |||
**Approximately 2% transform per year, or 10.7% in five years.<ref name=pmid23897955/> | |||
==Gross== | ==Gross== |
edits